Vol. 6 No. 3 (2014)

Artigos

• Cost-effectiveness of dasatinib versus nilotinib for the secondline treatment of patients with chronic myeloid leukemia (CML) under the Brazilian Private Healthcare System

  Rafael Araujo, Kélem Chagas, Camila Nabeshima, Camila Pepe, Graziela Bernardino, Bonnie Donato

  111-120

  • PDF (Português (Brasil))

• Economic benefits from the use of parecoxib for pain control in adult patients undergoing surgical procedures and renal colic

  Cristina Ferreira, Adriana Ribeiro, Camila Souza, Carlos Felipe Santana, Irimar Posso

  121-128

  • PDF (Português (Brasil))

• Alignment between strategy, structure and effects on the financial performance: study case of the Hospitalar Complex

  Djair Picchiai, Silvia Inês Sauma

  129-140

  • PDF (Português (Brasil))

• Critical analysis of the licensing regulation for biosimilar products in Latin American countries in relation to the guidelines of the World Health Organization

  Maria Angélica Maioli

  141-149

  • PDF (Português (Brasil))

• Preliminary analysis of chemotherapy waste cost

  Adriano Hyeda, Élide Costa

  150-155

  • PDF (Português (Brasil))